Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynecologists
D. Vavilis1,*, K. Chatzigeorgiou2, D. Goulis1, K. Pantazis1, A. Papanicolaou1, T. D. Theodoridis1, B. C. Tarlatzis1
1 1st Department of Obstetrics and Gynecology, “Papageorgiou Hospital”, Aristotle University of Thessaloniki
2 4th Department of Obstetrics and Gynecology, “Hippokrateion Hospital”, Aristotle University of Thessaloniki (Greece)
Eur. J. Gynaecol. Oncol. 2011, 32(5), 538–541;
Published: 10 October 2011
Purpose of investigation: In this survey we evaluated the prescription attitude of Greek gynecologists towards hormone replacement therapy (HRT) for ovarian cancer survivors. Methods: An anonymous questionnaire was sent to 900 members of the Hellenic Society of Obstetrics and Gynecology presenting a hypothetical case of an ovarian cancer survivor with indications for HRT followed by a series of relevant questions. Results: Two hundred and ninety-eight responses were analyzed with regards to age, gender and practice setting. HRT would be prescribed by 48% of Greek gynecologists; regarding type of regimen, 60% would prescribe tibolone, 19% estrogen alone and 21% estrogen plus progestagen. In contrast, 52% of Greek gynecologists would not prescribe HRT due to the fear of ovarian cancer relapse (83%), or the development of breast cancer (6%), or both cancers (9%); among them, 21% would alternatively prescribe CNS medications, 9% SERMs, phyto-estrogens or bisphosphonates, while the remaining 70% would not prescribe anything. Conclusions: One out of two Greek gynecologists would prescribe HRT in ovarian cancer survivors. An alternative therapy, mainly CNS medications, would be suggested by 21% of the opposers.
Ovarian cancer survivors
Hormone replacement therapy